Incannex secures $10M to fast-track sleep apnea treatment trials

Incannex Healthcare has secured $10 million in fresh funding through a private share placement. The Australian biotech firm will use the capital to push forward its lead treatment for obstructive sleep apnea, IHL-42X, as it prepares for a key dosing study later this year.

The company also announced the end of an earlier equity offering programme to strengthen its financial position ahead of upcoming clinical trials.

The new funds came from issuing two million units at $5.00 each. Every unit includes one share and a warrant allowing investors to buy an additional share at $6.50 before March 2031. Incannex's stock closed at around $3.27 over the weekend, valuing the company at approximately $38.1 million.

The money will mainly support the DReAMzz Phase 2 trial, which aims to fine-tune the dosage of IHL-42X. Positive results from this study could lead to a Phase 3 programme starting in late 2027. Earlier data from the RePOSA trial showed promising outcomes: 58% of participants saw a notable drop in their Apnea-Hypopnea Index (AHI), with high-dose groups achieving reductions of up to 83%. No serious side effects were reported.

Incannex is also using the FDA's 505(b)(2) pathway to speed up potential approval. This route allows the company to rely on existing safety data for similar drugs, cutting development time. The FDA has already granted IHL-42X Fast Track status, which could further accelerate the review process.

The RePOSA study also highlighted that reducing AHI through repositioning therapy improved cardiovascular health and daytime symptoms in patients. While these findings are encouraging, continuous positive airway pressure (CPAP) remains the standard treatment for severe sleep apnea cases.

The $10 million injection will help Incannex advance its clinical pipeline and refine its financial strategy. With Fast Track designation in place and a Phase 2 trial on the horizon, the company is moving closer to potential regulatory approval for IHL-42X. The next key milestone will be the dosing optimisation results, expected to shape the Phase 3 programme planned for 2027.